Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2021 Webinar: Genetics of NAFLD

    Contains 2 Component(s) Recorded On: 07/27/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on July 27, 2021.

    In this webinar, you will learn how to describe nonalcoholic fatty liver disease (NAFLD) as it relates to genes in animal and human models, their role, function and related pathways. Also, the focus on NAFLD-related genes in human studies and their relationship to disease severity. Lastly, can you use the genes in a precision medicine approach?

    Silvia Sookoian

    Silvia Sookoian, MD, PhD, FAASLD is head of Clinical and Molecular Hepatology Department, Institute of Medical Research IDIM-National Scientific and Technical Research Council (CONICET), School of Medicine, University of Buenos Aires. She is also the Vice-Chair of Institute of Medical Research, IDIM-CONICET, School of Medicine, University of Buenos Aires. Dr. Sookoian received her medical degree with honors in the University of Buenos Aires, Scholl of Medicine (magna cum laude). She completed her residency in Internal Medicine in Cosme Argerich Hospital Associated to the University of Buenos Aires. Argentina. She received her PhD degree in Molecular Medicine in the University of Buenos Aires. Argentina. She has been in clinical practice since 1987 (Clinical Training Board certificated in Internal Medicine; Fellowship in Hepatology). She received training in Hepatology (Hepatology Centers of Excellence Program Sweden), GI–Liver pathology (Armed Forces Institute of Pathology, Washington DC), and genetics of complex diseases (Cold Spring Harbor Laboratories USA and Wellcome Trust Advanced Courses). She was awarded as Fellow of the American Association for the Study of Liver Diseases (FAASLD), which recognizes superior professional achievement in liver research and practice.

    Dr. Sookoian’s current clinical and translational research is focused on genetic, epigenetic, and molecular mechanisms implicated in non-alcoholic fatty liver disease pathogenesis and disease progression. She is involved in both clinical and basic research. She co-authored 172 peer-reviewed on manuscripts on the field of liver diseases. She was involved in pioneer studies on genetics, epigenetics, and tissue microbiome of NAFLD, and the use of OMICs resources to understand the disease biology.  

    Yaron Rotman

    Yaron Rotman, MD, MSc, FAASLD is a clinical investigator and acting chief of the Liver and Energy Metabolism Section in the Liver Diseases Branch of NIDDK. He received his MD and MSc in Neurophysiology degrees from the Hebrew University Hadassah Medical School in Jerusalem, Israel. He subsequently trained in Internal Medicine and Gastroenterology and Hepatology at the Rabin Medical Center in Petach-Tiqva, Israel, before joining the NIDDK Liver Diseases Branch as a fellow, and subsequently as a principal investigator.

    Dr. Rotman’s research focuses on mechanistic questions in non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in the western world. He is utilizing mechanistic clinical trials, human genetics, animal models and in vitro systems to understand mechanisms of hepatic fat accumulation and associated injury. 

    Luca Valenti

    Luca Vittorio Valenti, MD, PhD is an associate professor of Internal Medicine and physician scientist for the Department of Transfusion Medicine and Hematology at Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Italy. His main research interest is understanding the molecular basis of metabolic liver diseases, in particular FLD, iron overload disorders and liver cancer, and to apply these discoveries to the clinical management of patients, through the identification of novel biomarkers, therapeutic strategies and clinical algorithms, in a personalized medicine approach. In collaboration with his international network, he has recently discovered new genetic determinants of FLD. In the iron field, he contributed to establishing the role of body iron accumulation in the pathogenesis of metabolic and cardiovascular complications of insulin resistance, and the therapeutic utility of iron depletion. He uses a variety of tools ranging from epidemiological studies in large cohort of individuals with liver biopsies to human and molecular genetics to understand how a gene mutation results into a phenotype.

    Prof. Valenti has served as reviewer for several international Journals (>60) including New England Journal of Medicine, The Lancet, Gastroenterology, Gut, Journal of Clinical Investigation, HEPATOLOGY, Journal of Hepatology, Nature Communications, Circulation, Diabetes, Blood, several Scientific Societies (EASL, AISF), European Institutions. Since 2019, he is Honorary Member of Institute of Hepatology at the King’s College of London, the Liver Trust. He is considered an opinion leader in the field of metabolic liver diseases, as testified by invited talks and moderations of scientific sessions in scientific meetings and seminars in Italy, Europe, Asia, and the USA.

    Anna Mae Diehl (Moderator)

    Anna Mae Diehl, MD, FAASLD is currently the Florence McAlister Professor of Medicine at Duke University.  She is a physician scientist and academic hepatologist.  Her lab-based research activities focus on basic mechanisms of liver repair and complement her translational/clinical research programs in alcoholic- and nonalcoholic fatty liver disease.  In the past two years, Dr. Diehl she has co-authored ten peer-reviewed manuscripts on these topics.

    Her basic research program has enjoyed uninterrupted NIH RO1 support since 1990 and she has been the Principal Investigator for the NASH CRN UO1 clinical research program at Duke since its inception over 15 years ago. Dr. Diehl’s research contributions to the fields of regenerative medicine, alcohol-related liver disease and NAFLD have been acknowledged by election for membership in the American Society for Clinical Investigation, Interurban Clinical Club, Association of Academic Professors and Johns Hopkins University Society of Scholars, as well as awards such as an NIH/NIAAA Merit Award, the NIAAA Mendelson Award, the Duke Distinguished Faculty Award, and the AASLD Distinguished Scientific Achievement Award. 

    Dr. Diehl has been an associate editor/editorial board member for major journals such as HEPATOLOGY, Gastroenterology, GUT, The American Journal of Physiology, The Journal of Clinical Investigation, Nature Reviews, and eLife.  In addition, she has served as a standing member of several NIH study sections and scientific advisory councils for NIDDK, NCI, NIAAA, the American Liver Foundation, the Alcoholic Beverage Medical Research Foundation, NIDDK Digestive Disease Centers at Baylor, USC and U Pittsburgh, and NIAAA Alcohol Research Centers at U Louisville and the Cleveland Clinic.  

  • 2021 Webinar: Gaps in Advance Care Planning at Transplant Centers: Call for Action

    Contains 2 Component(s) Recorded On: 07/13/2021

    Webinar hosted by the Public Health/Health Care Delivery on July 13, 2021.

    There is increasing interest to integrate palliative care (PC) within routine practice of decompensated cirrhosis to enhance and inform clinical care. It has shown to improve patient- provider communication, provider awareness of symptoms, tailored symptom management enhance quality of life, ultimately with a better end of life care. There is minimal knowledge on what key elements of PC can inform care, particularly if advance care planning (ACP) has a role to play within Transplant Evaluation. 

    Arpan A. Patel

    Aran A. Patel, MD, PhD is a transplant hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center and core investigator at the VA Center for the Study of Healthcare Innovation, Implementation and Policy (CSHIIP) in Los Angeles. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai. He completed a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA in 2020. 

    Dr. Patel’s career goal is to ensure that patients with advanced liver disease receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Manisha Verma (Moderator)

    Manisha Verma, MD, MPH, currently serves as the Director of Research at the Department of Digestive Diseases and Transplantation at Einstein Healthcare Network, Philadelphia, and as the Assistant Professor of Medicine, Research at Sidney Kimmel Medical College. Her program of research focuses on patient centered outcomes research (PCOR) within Hepatology and beyond.  She and her team received a 15 million research award from the Patient Centered Outcomes Research Institute to conduct a multi-site cluster randomized study to compare two models of palliative care delivery for ESLD. She has contributed to advances in knowledge of clinical applications of Health Services Research, specifically in the areas of clinical integration of patient reported outcomes assessments,  integrated care models (palliative care and behavioral health), and population-based health approaches. 

    In her role, she is responsible for promoting and facilitating leading edge research, including collaborative and interdisciplinary research, in areas related to the mission of the Department (to advance patient care, education and new treatments for liver diseases). She serves as the Steering Committee member for the American Association for Study of Liver Diseases (AASLD) Public Health / Healthcare Delivery Group and as the Vice Chair for the Education Subcommittee. Dr. Verma has won both the Albert Einstein Society Innovative Awards and Albert Einstein Society Research Awards as a Principal Investigator since 2015 onwards.  The studies supported from these awards have led to development of a PCOR Pillar within the Department. 

    Brett E. Fortune (Moderator)

    Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation.

    Dr. Fortune’s research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

  • Fundamentals of Liver Disease - Cirrhosis 2.0

    Contains 31 Component(s), Includes Credits Recorded On: 07/12/2021

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    Does My Patient Have Cirrhosis?
    Natural History of Cirrhosis and General Management of the Compensated Patient
    Varices and Variceal Hemorrhage
    Ascites
    Hyponatremia and Hepatorenal Syndrome
    Hepatic Encephalopathy
    Infections in Cirrhosis
    Pulmonary Complications in the Patient with Cirrhosis
    Does my Patient with Cirrhosis Need to be Referred for Liver Transplant?

    Release date: July 12, 2021
    Expiration date: July 11, 2024
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 4.50 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of:
    -9 online interactive, narrated modules 20 to 25 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objective:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS  Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by July 11, 2024

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by July 11, 2024

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by July 11, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2024 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Patrick Kamath

    Patrick S. Kamath MBBS, MD, DM is Professor of Medicine and Consultant in Gastroenterology and Hepatology at the Mayo Clinic College of Medicine and Science, Rochester, Minnesota. He graduated in 1976 from St John’s Medical College in Bangalore and subsequently, underwent postgraduate training at the Postgraduate Institute of Medical Education & Research (PGIMER) in Chandigarh, the premier medical post-graduate training Institute in India. He received the Jane and Camillo Patrao Prize in Medicine at St John’s Medical College, and the Kataria Gold Medal (an award for the most outstanding postgraduate student) at the PGIMER.  He completed both his MD in Medicine (1980) and is DM in Gastroenterology (1982) at the PGIMER.  On his return to Bangalore in January 1983 he joined St John’s Medical College, Bangalore University and quickly rose to the position of Associate Professor and then Professor and Chief at the Department of Gastroenterology. At a national and international level, Patrick S. Kamath has been honored with the Distinguished Educator Award of the American Gastroenterology Association in 2015 and the Distinguished Educator/Mentor award of the American Association for the Study of liver Diseases in 2018. He delivered the Eugene Schiff oration at the AASLD annual meeting in 2017. 

    Professor Kamath’s academic research has appeared in top-ranking journals including the New England Journal of Medicine, Nature Genetics, the Lancet, British Medical Journal, Gastroenterology, Hepatology, and the Journal of Hepatology.  He has served as Associate Editor at different times for the foremost journals in the field: Hepatology, Clinical Gastroenterology and Hepatology, and Journal of Hepatology. With more than 500 papers to his name, he has published widely in various fields, but particularly in the study of clinical outcomes related to cirrhosis and portal hypertension, vascular diseases of the liver, and polycystic liver disease.  He has written over 100 chapters in standard texts.  However, he is mostly known for his work in the development of the Model for End-Stage Liver Disease (MELD) score.  

    Guadalupe Garcia-Tsao

    Guadalupe Garcia-Tsao, MD, FAASLD is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Juan G. Abraldes

    Juan G. Abraldes, MD is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004).

    He has published over 200 manuscripts on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis. He was the chair of the AASLD Portal Hypertension Special Interest Group from 2017-2018.

    Florence Wong

    Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.

    She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.

    She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.

    Raimund Pichler

    Jasmohan S. Bajaj

    Jasmohan S. Bajaj, MBBS, MD, MS, FACG, AGAF, FRCP, FAASLD is Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and Richmond, VA Medical Center in Richmond, VA. He is a Fellow of the American College of Gastroenterology, American Gastroenterological Association, American Association for the Study of Liver Diseases, was elected to the Fellowship of the Royal College of Physicians in London and to the American Society for Clinical Investigation. Dr. Bajaj earned his MBBS from Delhi University at Maulana Azad Medical College. He completed an internship in internal medicine at Delhi University at Maulana Azad Medical College and internal medicine residency at the State University of New York Health Science Center in Brooklyn. He furthered his medical training with a fellowship in gastroenterology and hepatology at the Medical College of Wisconsin Affiliated Hospitals, then went on to earn an MS in epidemiology at the Medical College of Wisconsin in Milwaukee.

    Active in research, Dr. Bajaj has served as a principal investigator or co-investigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. Dr. Bajaj’s research has been funded through the NIH, US Veterans Affairs, AHRQ, and American College of Gastroenterology. His work has been published in Nature, New England Journal of Medicine, Gastroenterology, Journal of Hepatology, Hepatology, The American Journal of Gastroenterology, and Liver Transplantation, among others. Dr Bajaj is the upcoming Co-Editor in Chief for the American Journal of Gastroenterology and is currently an associate Editor for the Red Journal and Gut Microbes. He is on the editorial board for Journal of Hepatology, Hepatology, and Liver Transplantation. He was a member of the AASLD/EASL Hepatic Encephalopathy Guidelines Writing Committee, is the Chairperson of the Acute-on-Chronic Liver Failure ACG Clinical Guidelines and a member of the AASLD ICU and ACLF Guidance committee. He is also a member of the AASLD Clinical Research Committee. Dr Bajaj is the Chairperson for the North American Consortium for Study of End-Stage Liver Disease and was the immediate Past President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism.

    Puneeta Tandon

    Puneeta Tandon, MD, FRCPC is an associate professor of medicine, co-director of the Cirrhosis Care Clinic and transplant hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her internal medicine, hepatology and clinical epidemiology training at the University of Alberta with additional training at Yale University and the Hospital Clinic in Barcelona.

    Dr. Tandon’s clinical practice and research are focused on cirrhosis with research interests including cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care and integrative health approaches such as meditation and behavior change techniques. It is her career goal to provide wholistic, interdisciplinary, patient-centered care through evidence, education, empowerment, engagement and teamwork.


    Michael B. Fallon

    Michael B. Fallon, MD, FAASLD is Professor and Chair of the Department of Medicine at the University of Arizona College of Medicine – Phoenix (UACOMP). A national expert in transplant hepatology and pulmonary complications of cirrhosis, he is actively involved in translational and multicenter clinical studies of hepatopulmonary syndrome and portopulmonary hypertension. He has over 140 publications with 30 years of academic medicine experience including extensive patient care, education, leadership and clinical investigation in internal medicine. In his role as Chair of the Department of Medicine, Dr. Fallon provides executive leadership to many of the multidisciplinary programs at Banner – University Medical Center Phoenix, ten UACOMP divisions, and more than 160 residents and fellows.

    Dr. Fallon has received numerous awards recognizing his accomplishments in academic medicine including teaching, research and innovation.  Additionally, he has held numerous leadership positions in professional organizations including multiple committees of the American Association for the Study of Liver Disease, member of the American Board of Internal Medicine Transplant Hepatology Test Committee for 9 years and is a past senior associate editor of Clinical Gastroenterology and Hepatology.  He also serves as the lead author for the Diseases of the Liver and Biliary System Chapters for Cecil Essentials of Medicine for the past 15 years.

    Paul Martin

    Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA. He is a native of Dublin, Ireland, where he graduated from medical school at University College, Dublin. He specialized in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Medical Staff Fellow in the Liver Unit, NIH, Maryland, USA. He is Editor-in Chief of Liver Transplantation and Editor of Handbook of Liver Disease. He was previously a Councilor for AST of the American Society of Transplant. He has had a long standing interest in viral hepatitis and organ transplant. 

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The faculty, organizers and reviewers have reported the following disclosures:

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Guadalupe Garcia-Tsao, MD, FAASLD
    Faculty
    Nothing to disclose

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD, FRACP, FRCPC
    Faculty
    Consulting: Sequana

    Raimund Pichler, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD, MS, FACG, AGAF
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix and Norgine 
    Grant/Research Support: Grifols, Salix

    Puneeta Tandon, MD, FRCPC
    Faculty
    Nothing to disclose

    Michael Fallon, MD
    Faculty
    Grant/Research Support: Gore

    Paul Martin, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead, Thera, Mallinckrodt, Viking, Durect and Enanta

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalties: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Sonal Kumar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    April G. Morris, FNP
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

    Paul Pockros, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Melissa Morrison
    AASLD Staff
    Nothing to disclose

    Melanie Stanton, CAE
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • 2021 Webinar: NASH as a Cause of Hepatocellular Carcinoma

    Contains 2 Component(s) Recorded On: 06/16/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on June 16, 2021.

    Learn about epidemiology of NASH-HCC, differences in NASH-HCC compared to other etiologies and prevention and management of NASH-HCC. Presenters will discuss the rising burden of NASH-HCC such as its contribution to liver transplant, morbidity and mortality and cost. Along with differences in gender, presentation, prognosis and screening data, prevention, treatments such as resection versus liver transplant versus other therapies.

    Zobair M. Younossi

    Zobair M. Younossi, MD, MPH, FAASLD is the President of Inova Medicine, Inova Health System as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus in Falls Church, Virginia. He is also Chair of Clinical Research at the same institution. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, NY and completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. He initially served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation in Cleveland, Ohio before establishing the Center for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as its Chair of Research.

     Over the past three decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. Dr. Younossi has authored over 590 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. 

    Julia J. Wattacheril

    Julia Wattacheril, MD, MPH is an associate professor of medicine and director of the Nonalcoholic Fatty Liver Disease program at Columbia University Irving Medical Center. Her clinical and translational work spans the multidisciplinary care of NAFLD patients at all stages of their disease to the investigation of rare genetic variants influencing the development and progression of NAFLD before and after liver transplantation. She currently leads an interdisciplinary research group using semi-automated techniques to identify at-risk and protected phenotypes within the electronic health record (EHR) for genomic analysis.  Of particular interest for clinical outcomes discovered through EHR phenotyping include rapid progression to advanced liver disease, need for transplantation and hepatocellular carcinoma. 

    Dr. Wattacheril is the lead principal investigator for several clinical trials in and serves as the clinical lead for the liver precision medicine initiative at Columbia. Her early pilot work with proteomics and lipidomics in the development of nonalcoholic steatohepatitis (NASH) led to her current efforts investigating the transcriptomic signatures associated with metabolic reprogramming associated with fibrotic NASH.  She co-led a multicenter consortium investigating the clinical risks associated with the development of hepatocellular carcinoma in patients with all etiologies of chronic liver disease, with a particular local focus on diverse populations.  At Columbia, she works closely with the Institute for Genomic Medicine and Center for Precision Medicine and Genomics to integrate genomics into clinical care. She mentors across disciplines including computational geneticists to masters’ program students in nutrition to undergraduates in psychology. She has a commitment to community education especially in communities of color, including faith-based and non-profit sectors. She has served on the Clinical Research Committee for AASLD and is part of multistakeholder groups such as the NIMBLE Consortium and Liver Forum in addition to other professional society memberships. 

    Samer Gawrieh

    Samer Gawrieh, MD is an associate professor of Clinical Medicine and the director of the Hepatology Research Fellowship Program in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine. His clinical and translational research focuses on different aspects of non-alcoholic and alcoholic fatty liver disease including machine learning-based histological phenotyping, genetic modifiers and diagnostics. He also studies hepatocellular carcinoma (HCC) associated with these diseases with a particular focus on non-cirrhotic HCC.

    Dr. Gawrieh is NIH funded to study NAFLD and NASH in persons living with HIV. He is also the Clinical Director of the Data Coordinating Center for the NIH-sponsored alcoholic hepatitis network, a national network of eight leading academic centers in the US that studies different aspects and therapeutics of alcoholic hepatitis. Dr. Gawrieh is a member of the Editorial Board of Clinical Gastroenterology and Hepatology. 

    Fasiha Kanwal (Moderator)

    Fasiha Kanwal, MD, MSHS, AGAF, FAASLD is a professor of medicine and chief of Gastroenterology and Hepatology at Baylor College of Medicine. She also serves as the editor-in-chief for Clinical Gastroenterology and Hepatology, the American Gastroenterological Association clinical practice journal.  She is a nationally recognized authority in health services research and epidemiology of cirrhosis and hepatocellular cancer (HCC). 

    Dr. Kanwal is currently leading a translational research center for the National Cancer Institute Consortium on Translational Research in Early Detection of Liver Cancer (TLC, U01). She also serves as co-PI for the Texas HCC Consortium (THCCC) and as one of the co-Directors for the Texas Collaborative Center for HCC (TeCH). She is also the Director for NIH T32 funded GI fellowship program at Baylor College of Medicine.

  • 2021 Webinar: Natural History of NAFLD/NASH in Children: Knowledge, Gaps and Interventions

    Contains 2 Component(s) Recorded On: 06/02/2021

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on June 2, 2021.

    The gap in natural history data for NAFLD/NASH in children is large, but there have been some significant advances made in the past couple of years. This webinar aims to increase awareness, enhance knowledge and improve health of children with this disorder.

    Shikha Sundaram

    Shikha S. Sundaram, MD, FAASLD, is an associate professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine. As a pediatric hepatologist and translational researcher with expertise in pediatric NAFLD, she studies the impact of chronic intermittent hypoxia on disease progression.

    Dr. Sundaram is a member of the AASLD NASH Task Force and the Annual Meeting Education Committee. She has published extensively in pediatric NAFLD, but also on the impact of undernutrition on pediatric liver disease as well as long term outcomes in pediatric liver disease and transplantation. She serves on the board of the National Charity League and on the Medical Advisory Committee for the Rocky Mountain American Liver Foundation and Round Up River Ranch.

    Samar Ibrahim (Moderator)

    Samar Ibrahim, M.B.Ch.B is an associate professor of Pediatrics and Physiology at the Division of Pediatric Gastroenterology and Hepatology in Mayo Clinic. Dr. Ibrahim is a pediatric  transplant hepatologist  and a physician scientist. Her research focus is to study the mechanism of liver injury and inflammation in nonalcoholic steatohepatis (NASH), with  the goal to identify novel biomarkers and mechanism-based therapeutic targets. Her recently published work identified the vascular adhesion molecule 1 (VCAM1) as a potential novel therapeutic target in NASH. Dr. Ibrahim and her research team have examined the role of extracellular vesicles as biomarkers, as well as mediators of intercellular communication in NASH pathobiology. They recently defined the role of integrin beta1-enriched extracellular vesicles in NASH. Dr. Ibrahim serves as the medical director of the pediatric liver transplant program at Mayo clinic, and is interested in studying factors responsible for late liver graft dysfunction, as well as developing models that better predict the acuity of the pediatric liver transplant candidate on the wait list.

    Dr. Ibrahim is a member of the editorial board for HEPATOLOGY and the American Journal of Physiology, gastrointestinal and liver physiology. She is currently and active member of the hepatology committee at the North American Society of Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) and the education committee and the advocacy committee at the study of pediatric liver transplant (SPLIT).  Dr. Ibrahim serves on the steering committee for the pediatric SIG at AASLD. Dr. Ibrahim is the Principal Investigator of the lipotoxicity and liver inflammation laboratory at Mayo Clinic.  She is an active member of the center of cell signaling in gastroenterology at Mayo Clinic and moderates the center weekly scientific seminar series. Dr. Ibrahim has served on  NIDDK study sections, as well as a reviewer for international funding agencies. Dr. Ibrahim  has mentored numerous medical students, residents, and postdoctoral fellows.

    Rohit Kohli (Moderator)

    Rohit Kohli, MBBS, MS, FASSLD is the chief of the division of Gastroenterology, Hepatology and Nutrition, and associates chair in Liver and Intestinal Research, at the Children’s Hospital Los Angeles. He is also a Professor of Pediatrics (Clinical Scholar) at the Keck School of Medicine at the University of Southern California. His clinical training and 20 years of experience have focused on caring for children needing liver transplant. Currently his administrative responsibility includes the highest ranked program for Pediatric Gastroenterology on the West Coast of the United States. His clinical, translational and basic science research work has been focused on obesity-related fatty liver disease (NASH) and weight loss surgery with 15 plus years of continuous funding support from the National Institutes of Health.

    Dr. Kohli has served as editorial/advisory board member for major journals such as HEPATOLOGY, Pediatric Transplantation and Pediatric Obesity. He is currently Vice-Chair of the Pediatric Hepatology Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and a member of the nominating committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). He is an active teacher and educator, with the current added responsibility of being the director of the Pediatric Scientists Program (Donnell Scholar Program) at Children’s Hospital Los Angeles. 

  • 2021 Webinar: Challenges in NASH Clinical Trials

    Contains 2 Component(s) Recorded On: 05/19/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on May 19, 2021.

    Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Presenters will also discuss how to implement hard outcomes in NASH clinical trials and the use non-invasive biomarkers as primary endpoints for drug approval.

    Naim Alkhouri

    Naim Alkhouri, MD is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.

    Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX.

    Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.

    Dr. Alkhouri is a key opinion leader in the field of NASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies.  He is Principal Investigator on several multicenter global NASH trials and a member of the AASLD NASH Special Interest Group (NASH SIG). Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. Dr. Alkhouri's specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation. Dr. Alkhouri has been published in over 200 publications and presents his work at both national and international medical conferences.

    Manal F. Abdelmalek

    Manal F.Abdelmalek, MD, MPH, FAASLD is a tenured Professor of Medicine in the Divisionof Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty LiverDisease (NAFLD) Clinical Research Program at Duke University. Since firstreporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogeniccirrhosis nearly 25 years ago, her clinical and research area of interest hasfocused on NAFLD / NASH, associated risk factors for disease acquisition andprogression and the discovery of novel approaches to treatment.   She has expertise in clinical-translationalresearch, the design and conduct of clinical trials, includinginvestigator-initiated, industry sponsored and NIH-funded clinical studies evaluatingnew therapies and biomarkers for NAFLD and NASH.  She collaborates extensively to translate newcompounds to first-in-man clinical studies and translate clinic-to-bench andbench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisitionand progression and new compounds into first-in-man clinical studies.  She is the lead Principal Investigator onseveral multicenter global studies, a member of the AASLD Global Outreach andEngagement Committee and past member of the AASLD Clinical Research Committee. Dr.Abdelmalek is a Fellow of American College of Physicians, American College ofGastroenterology and American Association for the Study of Liver Disease.  She is a standing member of NASH ClinicalResearch Network (NASH CRN) for the past 15 years, has published more than 200manuscripts and currently serves on the Editorial Board of HEPATOLOGY, theofficial journal of the AASLD.  

    Mazen Noureddin

    Mazen Noureddin, MD, MHSc is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. His focus is on clinical and translational research in the area of NAFLD/NASH. Dr. Noureddin has conducted more than 35 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology”. He is also member of the incoming board of editors (2022) for Clinical Gastroenterology and Hepatology (CGH). He is funded by the National Cancer Institute. 

    Vlad Ratziu (Moderator)

    Vlad Ratziu, MD, PhD is a professor of hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a two-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.

    Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is a member of the organising committee of the NASH–TAG meetings. He is a co-editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 300 articles in top-tier specialty journals.

  • 2021 Webinar: Acute on Chronic Liver Failure (ACLF) in Alcohol-associated Liver Disease (ALD)

    Contains 2 Component(s) Recorded On: 04/29/2021

    Webinar hosted by the Alcohol-associated Liver Disease and Acute on Chronic Liver Failure Special Interest Group on April 29, 2021.

    Alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH) is the leading etiology for acute-on-chronic liver failure (ACLF) and need for liver transplantation. ACLF has a high short term mortality due to multiple organ failure. Further, criteria for patient selection for liver transplantation are heterogeneous especially in those with ALD and AH.

    Juan Pablo Arab

    Juan Pablo Arab, MD is an assistant professor of medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the Pontificia Universidad Catolica, Chile and Mayo Clinic, Rochester, MN, USA. Dr. Arab is a gastroenterology and hepatology specialist, transplant hepatologist and physician scientist with interest in translational and clinical research in alcohol-related liver disease and non-alcoholic fatty liver disease. He is the Director for Living Donor Liver Transplantation at his institution.

    Dr. Arab has published more than 100 peer-reviewed papers on gastrointestinal and liver diseases in high-impact factor journals, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings. He has also participated in the generation of clinical practice guidelines for alcohol-related liver disease, nonalcoholic fatty liver disease, and hepatorenal syndrome and regularly serves as expert reviewer of research grants and scientific research abstracts for multiple societies, funding agencies and international peer reviewed journals. Additionally, he is spearheading an international collaboration group that aims to study alcohol-related liver disease and non-alcoholic fatty liver disease. He is currently the Secretary of the Special Interest Group on Alcohol-associated Liver Disease of the American Association for the Study of Liver Diseases (AASLD) and Vice-Chairs its global outreach subcommittee. Additionally, he is the Vice-President of the Chilean Hepatology Association and he is member of the Education and Scholarship Committee of the International Liver Transplantation Society (ILTS).

    Lorenzo Leggio

    Lorenzo Leggio, MD, PhD, MSc is a physician-scientist who conducts clinical research on medication development and the role of neuroendocrine pathways in addictions. He is also an expert in the management and treatment of alcohol use disorder in patients with alcohol-related liver disease Dr. Leggio received his MD and PhD from the Catholic University of Rome and ‘Agostino Gemelli’ hospital (Italy), where he also completed residency and received Board Certification in Internal Medicine. He also received a masters in ‘Alcohol-related Diseases and Problems’ from the University of Florence. He was a visiting research associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University in Providence, Rhode Island. Throughout his career, he has worked as a faculty member and principal investigator at Brown University and National Institutes of Health.

    Jennifer C. Lai

    Jennifer C. Lai, MD, MBA is a general/transplant hepatologist, associate professor of medicine at the University of California, San Francisco (UCSF) and director of the UCSF Advancing Research in Clinical Hepatology (ARCH) program. Her mission is to improve the lives of patients with end-stage liver disease both at an individual level—through exceptional patient-centered care—and at a system-wide level—through rigorous clinical investigation and effective dissemination of impactful research. Her research lies at the intersection of hepatology, liver transplantation, and geriatrics, focusing on the application of aging research principles to the care of liver transplant patients across their life-long journey from diagnosis of advanced chronic liver disease through long after liver transplantation. The foundation for her research is the NIH-funded Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.

    Dr. Lai earned her undergraduate degree from Stanford University and combined MD/MBA degrees from Tufts University. She completed residency at the New York Presbyterian Hospital-Columbia followed by gastroenterology and transplant hepatology fellowships at UCSF. She serves as Associate Editor for the American Journal of Transplantation, member for the Editorial Boards for HEPATOLOGY and for Liver Transplantation and standing member on the FDA Gastrointestinal Drug Advisory Committee.

    Ashwani K. Singal (Moderator)

    Ashwani K. Singal, MD, MS, AGAF, FACG, FAASLD is a professor of medicine at the University of South Dakota Sanford School of Medicine and transplant hepatologist at the Avera transplant institute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford Medical School and is Chief of clinical research affairs at the Avera transplant institute. 

    With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry. He has over 200 original peer reviewed articles in national / international journals and book chapters. He is on the editorial board of many journals including Liver Transplantation, co-editor in chief for Translational Gastroenterology Hepatology, and associate editor for Digestive Liver Disease, PLoS one, Journal of Clinical Translational Hepatology and Journal of Clinical and Experimental Hepatology. Apart from reviewing research grants and scientific research abstracts for the AGA and AASLD, Dr. Singal is on the study section for the NIH. He is lead author on practice guidelines for alcoholic liver disease, has co-authored guidelines on vascular disorders of the liver and is currently involved in writing guidelines on nutritional management of patients with cirrhosis. Dr. Singal has been awarded the prestigious Edgar Achkar Visiting Professorship by the ACG and also chairs the special interest group on Alcohol-associated Liver Disease of the AASLD.

    Winston Dunn (Moderator)

    Winston Dunn, MD is an associate professor for the University of Kansas Medical Center. His expertise includes alcoholic associated liver disease, NASH clinical trials and cirrhosis regression after HCV treatment.

    Dr. Dunn has served as editorial board member for Journal of Clinical and Translational Hepatology. He is currently the Education Chair of the Alcohol-associated Liver Disease (ALD) Special Interest Group Education Sub-Committee for the American Association for the Study of Liver Diseases (AASLD). He is the site Principal Investigator for several multinational studies involving NASH treatment. Currently his research is funded by K23 Mentored Patient-Oriented Research Career Development Award, Lied Pre-Clinical and Clinical Research Pilot Grant Program, and Gilead NASH Models of Care ISR Program.

    Constantine J. Karvellas

    Constantine (Dean) Karvellas, MD, SM, FRCPC is an associate professor of medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an adjunct professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a hepatologist.

    Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

    Puneeta Tandon

    Puneeta Tandon, MD, FRCPC is an associate professor of medicine, co-director of the Cirrhosis Care Clinic and transplant hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her internal medicine, hepatology and clinical epidemiology training at the University of Alberta with additional training at Yale University and the Hospital Clinic in Barcelona.

    Dr. Tandon’s clinical practice and research are focused on cirrhosis with research interests including cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care and integrative health approaches such as meditation and behavior change techniques. It is her career goal to provide wholistic, interdisciplinary, patient-centered care through evidence, education, empowerment, engagement and teamwork.


  • 2021 Webinar: FY21 Peer Reviewed Cancer Research Program Funding Opportunities in Liver Cancer

    Product not yet rated Contains 2 Component(s) Recorded On: 04/12/2021

    Webinar hosted by the Public Policy Committee on April 12, 2021.

    The Peer Reviewed Cancer Research Program webinar will present funding opportunities for liver cancer through the Department of Defense. This webinar will cover topics including how to apply, what opportunities are available, as well as hints and tips on how to succeed in applying to the Department of Defense Congressionally Directed Medical Research Programs.

    Donna M. Kimbark

    Donna M. Kimbark, PhD currently serves as the Program Manager at the Congressionally Directed Medical Research Programs, U.S. Army Medical Research and Development Command.

    In 1996, Dr. Kimbark received her PhD in Molecular Pharmacology and Cancer Therapeutics from the State University of New York at Buffalo, Roswell Park Cancer Institute. Following postdoctoral training at Johns Hopkins Medical Institute, Dr. Kimbark worked in the biotechnology sector before joining the Congressionally Directed Medical Research Programs (CDMRP) in 2002 as Science Officer for the Breast Cancer Research Program. During her time as a Science Officer, Dr. Kimbark also served on the Institution Based Research Program group and served as Chair of the Consumer Working Group. While working in grants management, she received her certificate in Epidemiology and Biostatistics from Drexel University. In 2008, Dr. Kimbark was promoted to Program Manager for the Peer Reviewed Cancer Research Program.  Throughout her years at CDMRP, Dr. Kimbark has led multiple research funding programs including Autism, Multiple Sclerosis, Kidney Cancer, and Bone Marrow Failure Research Programs. Currently, she leads the program teams for the Peer Reviewed Cancer Research Program and the Melanoma Research Program.  In addition to her programmatic duties, Dr. Kimbark also leads the Funding Opportunities Announcement team, where she coordinates the creation and revisions solicitation templates for grants. For her efforts, she has been awarded the Commander’s Award for Civilian Service. Her areas of expertise include cancer therapeutics, pharmacology, proteomics, and scientific research administration.

  • 2021 Webinar: Simultaneous Liver Kidney Transplant: How Did We Do With the New Criteria?

    Product not yet rated Contains 2 Component(s) Recorded On: 03/29/2021

    Webinar hosted by the Liver Transplantation and Surgery Special Interest Group on March 29, 2021.

    In this one hour on-demand webinar, we will discuss how we arrived at the new organ allocation schema for simultaneous liver kidney (SLK) transplants by UNOS in partnership with our Transplant Nephrologists and the effect this has had on dual organ allocation and outcomes of SLK transplantation.

    Ryutaro Hirose

    Ryutaro Hirose, MD is professor and vice chair of clinical operations and value for the Department of Surgery at the University of California, San Francisco. He is an active liver, kidney and pancreas transplant surgeon. He currently serves as the Surgical Director of the Scientific Registry of Transplant Recipients (SRTR). He is a Councilor-at-large for the American Society of Transplant Surgeons (ASTS).

    Dr. Hirose has served as the chair of the ASTS Fellowship Training Committee and the ASTS Standards and Quality Committee. He spearheaded the creation and development of a National Transplant Quality Program with the ASTS and the American College of Surgeons. He has served as vice chair and chair of the UNOS Liver and Intestinal Organ Transplantation committee and led the development and implementation of the new liver distribution system, the national liver review board, HCC and MELD exception policy and the Simultaneous Liver Kidney Transplant (SLK). He has served on the board of directors and chair of the medical advisory board of donor network west, the local organ procurement agency for Northern California. Dr. Hirose has served as an associate editor for Clinical Transplantation. He has also served as the associate program director of the UCSF Surgical Residency program for over 15 years. His academic and scholarly interests include ischemia-reperfusion injury, hepatocellular carcinoma, transplant outcomes and organ allocation and distribution policy, with over 120 peer-reviewed articles in these specific areas. As an active educator and advisor, he has mentored over 100 surgical residents, medical students, fellows and junior faculty, both at UCSF and other institutions.

    Richard Formica

    Richard N. Formica Jr., MD is a professor of medicine and surgery, director of transplant medicine and the medical director of the Kidney Transplant Program at Yale University School of Medicine. Dr. Formica is a practicing transplant nephrologist. He is currently the President of the American Society of Transplantation and the OPTN/UNOS Regional 1 Associate Counselor and the Region 1 Representative to the OPTN/UNOS Membership and Professional Standards Committee.

    Dr. Formica has extensive expertise in public policy as it pertains to the solid organ transplantation. He been an active participant in the United Network of Organ Sharing since 2009. During this involvement he held leadership positions as the Chairman of the Kidney Paired Donation Work Group, the Kidney Transplantation Committee and the Simultaneous Liver-Kidney Transplantation Working Group. In these roles, he participated in the design, public vetting and implementation of public policy regarding, living kidney donation, deceased donor kidney allocation and the medically appropriated and fair allocation of deceased donor kidneys with deceased donor livers. Dr. Formica has been involved with the Clinical Trials in Organ Transplantation since inception, having been a site PI on CTOT-1, CTOT-9, CTOT -17 and currently is the site PI for CTOT -19. Dr. Formica has authored or co-authored 79 peer reviewed manuscripts and numerous book chapters. He is currently the Associate Editor for the Clinical Journal of the American Society of Nephrology responsible for the transplant portfolio.

    David Mulligan (Moderator)

    David C. Mulligan, MD, FACS, FAST, FAASLD is an abdominal organ transplant surgeon performing both living and deceased donor liver, kidney and pancreas transplants. He currently serves as Professor and Chair of Transplantation and Immunology in the Department of Surgery at Yale University School of Medicine/Yale New Haven Health System. His clinical and academic focus surrounds living donor liver transplantation, expanding donation, and working on ways to utilize ex-vivo organ perfusion systems to increase transplantation in the U.S.

    Dr. Mulligan’s leadership in solid organ transplantation across national and international platforms has grown considerably and he now serves as the President of the United Network of Organ Sharing (UNOS)/Organ Procurement Transplant Network (OPTN), Member At-Large on the Governing Board of the American Association for the Study of Liver Diseases, Chair of the Advisory Council on Transplantation (ACOT) to the Secretary of HHS, Special Government Employee for FDA Medical Device Advisory Committee and Chair of the Business Practice Committee of the American Society of Transplant Surgeons. In these visionary roles, he has led major changes in organ allocation and distribution and will hopefully culminate in substantial increases in organ transplants. Passionate about patient-centered care and building more resilient teams, he makes time to share his enjoyment of spending time in nature, especially near the ocean, with his wife and three children.

    Michael L. Schilsky (Moderator)

    Michael L. Schilsky, MD, FAASLD completed his medical education at the University of Chicago, Pritzker School of Medicine and then trained in internal medicine and gastroenterology at The Albert Einstein College of Medicine. After a post-doctoral training fellowship at the Liver Research Center of the Albert Einstein College of Medicine he joined the faculty there and rose to the rank of Associate Professor.

    Dr. Schilsky moved to The Mount Sinai School of Medicine in 1989 to begin his work in the field of liver transplantation and was recruited in 2003 to the Weill Cornell Medical Center where he partnered with the transplant program at Columbia Presbyterian. Dr. Schilsky was again recruited in 2007 to Yale as Medical Director for the Liver Transplant program and rose to the rank of Professor of Medicine and Surgery. He also is a member of the NIH sponsored Acute Liver Failure Study Group and chairs their publications committee. He is a former UNOS Region 1 representative for the Liver and Intestine Committee and is the current Chair of the Special Interest Group for Liver Transplantation and Surgery sponsored by the American Association for the Study of Liver Disease (AASLD).

  • 2021 Emerging Topic Conference: Chronic Hepatitis B: From Population to New Molecules and Back

    Contains 10 Component(s), Includes Credits

    This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population. A review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers will be covered along with an assessment of HBV cure’s impact on HBV epidemiology and population health.

    This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population. A review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers will be covered along with an assessment of HBV cure’s impact on HBV epidemiology and population health.

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, evaluations, and continuing education credit claiming:
    - 19 online, narrated presentations 20 minutes in length 
    - Evaluation for CME credit/ABIM MOC point offerings 

    DIRECTIONS
    Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

    PRICING
    Member —  $175
    Trainee & Assoc. Members — $100
    Student Member —  $50
    Non-Member —  $225
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
    Trainee & Assoc. Non-Member —  $150
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
    Student Non-Member —  $75
    Industry —  $450
    Any Industry (pharma/device/etc.) employee with or without medical training.
    Patient / Patient Advocate — Free

    CANCELLATION POLICY (Ended March 11,2021

    - Requests for cancellations must be submitted in writing to meetings@aasld.org.
    - Cancellations received through March 11, 2021 at 11:59 pm ET are subject to a 20% cancellation fee.
    - Cancellations received on March 12, 2021 and after are non-refundable.

    CONTINUING EDUCATION
    Continuing Medical Education (CME): 7.00 AMA PRA Category 1 Credits™
    ABIM Maintenance of Certification (MOC): 7.00 ABIM MOC Points

    HOW TO EARN AND CLAIM MOC POINTS
    To claim both CME Credits and ABIM MOC points for this activity you must:  

                 o    Watch each video presentation
                 o    Complete the Final Evaluation
                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.
    MOC points are available for ABIM  board certified physicians only.

    Live Program Release Date: March 12, 2021
    Live Program Expiration Date: March 14, 2021

    Enduring Activity Release Date: May 17, 2021
    Enduring Activity Expiration Date: May 14, 2024

    Purchase Activity by: December 31, 2021

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    Upon completion of this activity, learners will be able to:

    • Identify populations to screen for HBV, to vaccinate, and to treat with focus on groups with controversial treatment indications.
    • Interpret results of new molecular and immunologic HBV cure biomarkers and learn about most updated HBV cure therapeutic development.
    • Detect areas of data gaps for future epidemiological, clinical, and translational research

    This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Professionalism, Systems-based Practice, Provide Patient-centered Care, Work in Interdisciplinary Teams, Employ Evidence-based Practice, Apply Quality Improvement, Utilize Informatics, Values/Ethics for Interprofessional Practice, Roles/Responsibilities, Interprofessional Communication, Teams and Teamwork 

    • Hepatologists
    • Gastroenterologists
    • Nurses
    • Nurse Practitioners
    • Pharmacists
    • Physician Assistants
    • Transplant Coordinators
    • Surgeons
    • Fellows/Trainees
    • Infectious Disease Specialist
    • Public Health Workers/Stake Holders
    • Epidemiologists
    • Virologists 
    • Immunologists
    • Industry Stakeholders

    ACCREDITATION AND DESIGNATION STATEMENTS
    Continuing Medical Education (CME)

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    CLAIMING CME CREDITS AND ABIM MOC POINTS
    CME Credits
    Physicians and other health care professionals seeking 7.00 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Thursday, April 15. The CME evaluation will be available to you upon completion of the live streaming conference.

    MOC Points
    Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Thursday, April 15. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM by the end of October 2021 for attendees who successfully complete the MOC evaluation.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Faculty

    Thomas Berg, MD, FAASLD
    Speakers Bureau: Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck, Novartis, Roche
    Scientific Consulting: Abbvie, Bristol Myers Squibb, Gilead, Merck/MSD, Janssen, Roche, Spring Bank
    Grants/Research Support: Abbvie, Bristol Myers Squibb,Boehringer Ingelheim, Gilead, Janssen, Merck/MSD, Novartis, Roche

    Robert S. Brown, MD, MPH, FAASLD
    Scientific Consulting: Gilead, AbbVie, Intercept, Shionogi
    Grants/Research Support: Gilead, AbbVie, Enanta, Intercept, Shionogi

    Kyong-Mi Chang, MD, FAASLD
    Advisory Board: Arbutus biopharma, Alnylam
    Scientific Consulting: Genentech

    Raymond T. Chung, MD, FAASLD
    Grants/Research Support: Abbvie, Merck, Boehringer Ingelheim, Gilead, Janssen, BMS, Roche, Synlogic, Kaleido, DSMB Alnylam (Uncompensated)

    Douglas T. Dieterich, MD, FAASLD
    Scientific Consulting: Gilead
    Grants/Research Support: Assembly

    Jordan J. Feld, MD, MPH, FAASLD
    Grants/Research Support: Abbvie, Alexion, Eiger, Enanta, Gilead, Janssen, Wako/Fujifilm
    Scientific Consulting: Abbvie, Arbutus, Deep Genomics, Eisai, Gilead, GSK, Roche

    Robert J. Fontana, MD, FAASLD
    Scientific Consulting: Sanofi
    Grants/Research Support: BMS, Gilead, Abbvie

    Marc G. Ghany, MD, MHSc, FAASLD
    Nothing to disclose.

    Robert G. Gish, MD, FAASLD
    Scientific Consulting: Abbott, AbbVie, Access Biologicals, Antios, Arena, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Exelixis, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Spring Bank, Viking Therapeutics, Biocollections, Fujifilm/Wako, Quest
    Leadership in related society: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch BioFund, HepQuant, Intercept, Janssen, Medimmune
    Speakers Bureau: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, Salix

    Yao-Chun Hsu, MD, MSc, PhD
    Grants/Research Support: Gilead Sciences
    Speakers Bureau: Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Novartis.
    Scientific Consulting: Gilead Sciences

    Ira M. Jacobson, MD, FAASLD
    Scientific Consulting: Abbvie, Arbutus, Arrowheard, Aligos

    Harry L.A. Janssen, MD, PhD, FAASLD
    Scientific Consulting: Arbutus, Enyo, Gilead Sciences, Janssen, Medimmune, Merck, Roche, Vir Biotechnlogy Inc., Viroclinics.
    Grants/Research Support: AbbVie, Arbutus, Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Merck, Roche

    Paul Kwo, MD, FAASLD
    Grants/Research Support: Gilead, Abbvie
    Scientific Consulting: Gilead, Abbvie

    Georg M. Lauer, MD, PhD
    Grants/Research Support: Janssen Pharma

    Seng Gee Lim, MD, MBBS, FAASLD
    Speakers Bureau: Gilead Sciences

    Anna S. Lok, MD, FAASLD
    Grants/Research Support: Bristol-Myers Squibb; Gilead; Target Pharma 
    Scientific Consulting: Huahui, Epigenomics, AIM, Ambys, Eli Lilly, Novo Nordisk, TARGET 
    Up To Date: Intellectual Property Rights 

    Mala Maini, MD
    Grants/Research Support: Gilead, Roche, Immunocore

    Paul Martin, MD, FAASLD
    Scientific Consulting: Abbvie, BMS, Merck, Gilead, Mallincrdot

    Brian J. McMahon, MD, FAASLD
    Nothing to disclose.

    Mindie H. Nguyen, MD, MAS, FAASLD
    Grants/Research Support: Gilead, B.K.Kee Foundation, NCI, Pfizer, Enanta, Vir, Glycotest 
    Scientific Consulting: Intercept, Eli Lilly, Exact Science (Amount received in 2020 was for service from 2019-2020 due to delay in payment. I am committed to not earn 10K or more a year in 2021 and after from this company or any other company during my term as part of the AASLD guidance writing group if selected)
    Leadership in related society: International Assoc for the Study of Liver Disease (Governing Council and Treasurer), Asian Health Foundation and Pacific Health Foundation (both 403c, Board  of Director); ACG (Clinical Practice Committee); AGA (Research Grant Panel); Gastro, APT, Lancet GI Hep, DDS, Life (Editorial Board); AFL Northern CA Chapter (Medical Advisory Board)

    George V. Papatheodoridis, MD, PhD, FAASLD
    Scientific Consulting: Abbvie, Dicerna, Gilead, Janssen, Merck Sharp & Dohme, Novartis, Roche, Spring-Bank 
    Grants/Research Support: Abbvie, Gilead, Janssen

    Barbara Rehermann, MD, FAASLD
    Nothing to disclose. 

    Norah Terrault, MD, MPH, FAASLD
    Grants/Research Support: Gilead Sciences, GSK, Roche-Genetech

    John Ward, MD
    Leadership in related society: Gilead Sciences, Abbvie, Abbott, Merck

    Heiner Wedemeyer, MD
    Scientific Consulting: Abbott, Abbvie, Altimmune, Biotest, Bristol Myers Squibb, BTG, Dicerna, Falk, Gilead, Janssen, MSD, MYR GmbH, Roche
    Grants/Research Support: Abbvie, Biotest, BMS, Gilead, Merck/MSD, Roche
    Speakers Bureau: Abbvie, Biotest, Janssen, MSD, Siemens

    Man-Fung Yuen, MD, PhD, DSc
    Scientific Consulting: AbbVie, Arbutus Biopharma, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals, Roche

    Basic Research Committee
    Bernd Schnabl, MD, FAASLD
    Grants/Research Support: CymaBay Therapeutics, Synlogic Operating Company, BiomX, Axial Biotherapeutics; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmacuticals, Ferring Pharmaceuticals, Patara Pharamaceuticals

    Laurie D. DeLeve, MD, PhD, FAASLD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Daiich Sankyo;  Intellectual Property Rights (Patents, Royalties, Licensing fees): COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES, 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment Southern California GBC ref.: 6177.132445PCT 

    Muyiwa Awoniyi, MD, PhD
    Nothing to disclose.

    Olivier Barbier, PhD, FAASLD
    Grants/Research Support: Canadian Institute for Health Research (public, Canada);

    Lily Dara, MD
    Nothing to disclose.

    Ariel E. Feldstein, MD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Gilead Merck ; Oppilan Pharma ; GSK

    Sandy Feng, MD, PhD
    Grants/Research Support: Novartis, Quark
    Leadership in related society: Board, Committee, Journal: Juno Therapeutics, Inc., America Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
    Stock/Stock Options: Amgen, Johnson & Johnson, Stryker, Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira

    Mercedes Fernandez, PhD
    Nothing to disclose.

    Heather L. Francis, PhD, FAASLD
    Nothing to disclose.

    Rohit Kohli, MBBS, MS, FAASLD
    Speaker's Bureau: Alexion Pharmaceuticals
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Takeda Pharmaceuticals
    Grants/Research Support: Epigen Pharma, Vision Pharmaceuticals
    Leadership in related society: NASPGHAN Foundation Board

    T. Jake Liang, MD, FAASLD
    Nothing to disclose.

    Pranoti Mandrekar, PhD, FAASLD
    Nothing to disclose.

    Laura E. Nagy, PhD, FAASLD
    Nothing to disclose.

    Kari Nejak-Bowen, MBA, PhD
    Nothing to disclose.

    Silvia M. Vilarinho, MD, PhD
    Nothing to disclose.

    Clinical Research Committee
    Ulrich Beuers, MD
    Nothing to disclose.

    Jasmohan S. Bajaj, MD, FAASLD
    Grants/Research Support: Valeant, Grifols
    Leadership in related society: Board, Committee, Journal: ACG: American Journal of Gastroenterology AE, AGA: Microbiome Scientific Advisory Board
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Valeant, Norgine

    Therese Bittermann, MD
    Nothing to disclose

    Edward Doo, MD
    Nothing to disclose

    Andrea A. Gossard, APRN, CNP
    Nothing to disclose

    Gene Y. Im, MD
    Nothing to disclose

    Mariana Lazo, MD, PhD
    Nothing to disclose

    Rohit Loomba, MD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Glympse bio, Metacrine, Viking, Ini Pharma Ionis, Intercept, Ionis, Janssen Inc., Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Madrigagal
    Grants/Research Support: Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Janssen, Madrigal Pharmaceuticals, Merck, NGM Disclosure updated: July      27, 2020 Biopharmaceuticals, Pfizer, and Siemens

    Arpan Arun Patel, MD
    Grants/Research Support: Gilead, Shire

    Shari S. Rogal, MD, MPH
    Nothing to disclose

    Emily J. Rothbaum Perito, MD
    Nothing to disclose

    Shimul A. Shah, MD
    Nothing to disclose

    Tracey G. Simon, MD
    Nothing to disclose

    James E. Squires, MD, MS
    Nothing to disclose

    Grace L. Su, MD, FAASLD
    Leadership in related society:  Member, Clinical Guidelines Committee, AGA; Company Employee, Officer, Director : My husband and son have equity interest in Applied Morphomics and Prenovo.

    Monica A. Tincopa, MD MSc
    Nothing to disclose

    Kymberly Watt, MD
    Expert testimony: Intercept - site- PI, Gilead - site PI, co-I, Conatus - site co-I, Novartis - previous site PI, co author study subanalysis, Pfizer- site co-I, all multicenter study related
    Stock/Stock Options: BMS; Arbutus; Madrigal; Viking

    AASLD Staff 
    Dominique Clayton
    Nothing to disclose

    Julie Deal
    Nothing to disclose 

    Matthew D’Uva
    Nothing to disclose

    Melanie Stanton
    Nothing to disclose

    Suzanne Thibeault
    Nothing to disclose

    Anne Wrobel
    Nothing to disclose 

    Thomas Berg

    Thomas Berg, MD, FAASLD is a Professor of Medicine at the University of Leipzig and Head of the Division of Hepatology for Leipzig University Medical Center, Germany. He specialized in internal medicine in 2001 and in Gastroenterology and Hepatology in 2007 at the University Medicine Berlin and became a lecturer in this subject in 2002.  His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials.

    Dr. Berg is Vice Secretary of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019.  He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 440 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 76 (Scopus).

    Robert Brown

    RobertS. Brown, Jr., MD, MPH is Vice Chair of Transitions of Care and Clinical Chiefof the Division of Gastroenterology and Hepatology in the Department ofMedicine at Weill Cornell Medical College. He is also Professor of ClinicalMedicine at Columbia University College of Physicians & Surgeons. Dr. Brownis the Director of the Center for Liver Disease and Transplantation at NewYork-Presbyterian Hospital.

    Dr.Brown received his bachelor degree from Harvard College, his medical degreefrom New York University and his Master of Public Health from the GraduateSchool of Public Health, University of California in Berkeley. Following thecompletion of his medical degree, he fulfilled his internship in Medicine atBeth Israel Hospital in Boston and his fellowship in gastroenterology andhepatology at the University of California in San Francisco.

    Hehas co-authored more than 200 peer-reviewed articles and mentored many traineesand junior faculty. He is the incoming Editor-in-Chief of Liver Transplantation, an Associate Editor for Hepatology, and published abook, Common LiverDiseases and Transplantation: An Algorithmic Approach to Work-up and Management.Dr. Brown is the recipient of a Young Investigator Award from the AmericanSociety of Transplant Physicians, the Senior Attending Teacher Award fromColumbia University Medical Center, and the American Liver Foundation New YorkChapter's Physician of the Year.

    Kyong-Mi Chang

    Kyong-Mi Chang, MD, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).

    Alfred S. Barritt

    Alfred Sidney Barritt IV, MD, MSCR is an associate professor in the UNC liver center at the University of North Carolina and is the interim medical director of liver transplantation and the transplant hepatology fellowship program director.  Dr. Barritt conducts clinical outcomes research in nonalcoholic fatty liver disease (NAFLD), general hepatology, and liver transplantation.  Dr. Barritt leads the UNC Liver Center’s clinical trial program in NAFLD where he is PI on multiple phase 2 and 3 industry sponsored clinical trials.  Dr. Barritt is a collaborator and advisor to multiple other investigators in the allied schools of health, including the Gillings School of Global Public Health, the Eshelman School of Pharmacy and the UNC School of Dentistry.  

    James J. Beaudoin

    James J. Beaudoin, PhD joined DILIsym Services, Inc., in 2020. He is involved in the ongoing development of the DILIsym modeling software, particularly the bile acid and cholestatic liver injury sub-models. He is also engaged in proprietary consulting projects including model development, simulations, and data analysis.

    Dr. Beaudoin received his PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill. His dissertation research focused on in vitro and modeling approaches to investigate mechanisms of DILI. Prior to his graduate training, he was a Data Coordinator II for the National NeuroAIDS Tissue Consortium, based at the University of Nebraska Medical Center. He obtained a M.S. in Molecular Medicine from Erasmus University Rotterdam, and a B.S. in Liberal Arts and Sciences from University College Utrecht, both based in the Netherlands. He also received pre-M.S. training in Biomedical Sciences from Leiden University, the Netherlands.

    Dr. Beaudoin has published over a dozen of scientific articles in the areas of drug and bile acid transporters, pharmacokinetics, drug toxicity, genetics of alcoholic hepatitis, and other human diseases. He received various awards during his academic training, including a NIH F31 Predoctoral Individual National Research Service Grant Award from NIDDK. He has been invited to speak at scientific and educational conferences, including the SOT Annual Meeting, the AAPS Drug Transporter Workshop, and the AACP Annual Meeting.

    James L. Boyer

    James L. Boyer, MD, FAASLD is the Ensign Professor of Medicine and Emeritus Director of the Liver Center at Yale University School of Medicine.  He is a graduate of Haverford College (1958) and the Johns Hopkins University School of Medicine (1962). From 1982 until 1996 he directed a combined Digestive Disease Section in the Department of Medicine at Yale.  He was the founding Director of the NIDDK funded Liver Center at Yale since 1984 and former Director of the NIEHS Center for Membrane Toxicity Studies at the Mt Desert Island Biological Laboratory in Salsbury Cove, ME where he was also Chairman of their Board of Trustees from 1995 to 2003 and 2011-2013.  He is past Chair, Board of Directors of the American Liver Foundation and a current member of Board of Mangers of Haverford College and Honorary Board member of the Mt Desert Island Biological Laboratory.  Dr. Boyer has a broad interest in all aspects of basic and clinical hepatology.  His laboratory has pioneered in understanding the cellular and molecular basis of bile formation and cholestasis and was supported by NIH for more than 40 years including two MERIT awards from NIDDK.  He is a member of the AASLD, ASCI, AAP, APS and ACCA and past president of both the American and the International Association for the Study of Liver Disease.  He is the recipient of Distinguished Achievement Awards from the AGA, AASLD and American Liver Foundation and the EASL International Recognition Award in 2020. 

    ​Nathaniel A. Brown

    Nathaniel A. Brown, MD is an Infectious Diseases physician with seven years’ fulltime employment in academic medicine (Asst Prof, UCLA School of Medicine, 1982-87; Assoc Prof, Cornell Medical College, 1987-89) followed by 31 years of pharmaceutic development experience, primarily in antiviral drug development (1989-2020).

     Dr. Brown studied Molecular Biophysics and Biochemistry as a Yale undergraduate and received his MD degree from Georgetown University School of Medicine. He completed clinical training in Pediatrics at The New York Hospital-Cornell Medical Center, and post-doctoral training in Infectious Diseases and Virology at Yale University School of Medicine.

    In his pharmaceutic career, Dr. Brown has had leadership roles in multiple Phase 1-3b clinical development programs, resulting in U.S. and global product approvals for six antiviral/anti-infective medicines:  two for hepatitis B, one for hepatitis C, two for HIV/AIDS, and one for Varicella.  He has extensive experience with globalized drug development, including North America, Europe, India, Southeast Asia, Japan, and China.  Now retired from fulltime work, his pharmaceutic positions included: Head, Opportunistic Infections Section, BurroughsWellcome Co. (1989-1994); Head, Hepatitis Section, GlaxoWellcome./GlaxoSmithKline (1994-2001); Chief Medical Officer positions at Idenix Pharmaceuticals (2001-2007), Presidio Pharmaceuticals (2009-2014), and Novira Therapeutics (2014-2016); and Chief Medical Advisor, Atea Pharmaceuticals (2018-2020).

    Dr. Brown has served in advisory roles for the Hepatitis B Foundation (Board of Directors), the NIH Div. of Extramural Grants, FDA’s Div. of Antiviral Products (Aug. 2002 HBV advisory meeting), and various pharma/biotech companies. He has chaired/co-chaired various scientific meetings, and authored/co-authored over 200 scientific articles, chapters, reviews, and abstracts.

    Naga P. Chalasani

    Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020.   He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology and Hepatology subspecialty training at Emory University in Atlanta. His research interests include CYP450 enzymes and liver disease and hepatic safety of xenobiotics. His research has been continuously funded by the National Institutes of Health since 1999.  He is currently the PI for three U01 awards and an R01 award from the National Institutes of Health. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles, 31 editorials/commentaries, 16 symposium proceedings, and more than 500 abstracts. He is the lead author for the AASLD Practice Guideline on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease and is the lead author on the ACG Practice Guideline on the Diagnosis and Management of Drug Induced Liver Injury. He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).

    Rachel Church

    Rachel Church, PhD is a Research Assistant Professor in the Department of Pharmacotherapy and Experimental Therapeutics within the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill. She also serves as the Director of UNC Organ Injury Biomarker Core that is part of UNC’s Institute for Drug Safety Sciences. Dr. Church received her B.S. degree from North Carolina State University and her Ph.D. from UNC Chapel Hill. Given the shortcomings of traditional measurements, the research of Dr Church aims to broaden the use and understanding of candidate biomarkers of organ injury, with a primary focus on clinical drug-induced liver injury. Dr. Church is also interested in identifying novel applications for traditional biomarkers that will improve their interpretation. Prior to joining UNC, Dr. Church was a Research Investigator at the Hamner Institutes for Health Sciences. 

    ​Robert J. Fontana

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

    Ira M. Jacobson

    Dr. Jacobson earned his BS from Yale University and MD from Columbia University College of Physicians and Surgeons. He trained as a fellow in gastroenterology and Hepatology at Massachusetts General Hospital and Harvard Medical School.  In 1984 he joined the faculty at Weill Cornell Medical College and New York Presbyterian Hospital.  During his 30 years at Weill Cornell, Dr. Jacobson served as Chief of the Division of the Gastroenterology and Hepatology from 1998-2015 as well as Medical Director of the Center for the Study of Hepatitis C. From 2015 to mid-2017 he was Chair of Medicine at Mount Sinai Beth Israel Medical Center, and Vice Chair of Medicine and co-Director of the Liver Institute at the Icahn School of Medicine at Mount Sinai.  He joined the faculty of NYU School of Medicine as Director of Hepatology on August 1, 2017.  

    Dr. Jacobson currently focuses on hepatitis B, fatty liver disease, and liver disease in Covid-19.  He has been an investigator in many trials on antiviral therapy for hepatitis B and C, including pivotal trials on interferon-based therapy and lead principal investigator and author for WIN-R trial (weight based ribavirin with peginterferon), ADVANCE (telaprevir), QUEST-1 (simeprevir), POSITRON (sofosbuvir), STARTVerso3 (faldaprevir), C-SALT (grazoprevir and elbasvir in advanced cirrhotics), and POLARIS-2 (sofosbuvir, voxilaprevir, velpatasvir) trials.    He has served on the Gastroenterology and Transplant Hepatology Boards of the American Board of Internal Medicine, as Associate Editor of the Journal of Hepatology, and as a reviewer for several other journals.  He has authored or co-authored over 250 peer-reviewed papers, chapters and reviews, including papers in the New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, Journal of Viral Hepatitis, Clinical Gastroenterology and Hepatology, and served as Co-Chief Medical Editor of HCV Next. He has edited two books on ERCP and a volume on hepatitis B for Clinics in Liver Disease. 

    Paul H. Hayashi

    Paul “Skip” H. Hayashi, MD, MPH, FAASLD is an adult hepatologist at the FDA.  He is DILI Team Lead in the Division of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research.  Prior to joining the FDA in February of 2020, he held positions in academia, civil service and uniformed service.  He received his BA in microbiology at University of California (UC) Los Angeles and medical degree at UC San Diego.  After completing residency and gastroenterology fellowship at UC Davis, he completed a clinical research fellowship in the Liver Diseases Section, National Institutes of Health, Bethesda, MD as a public health officer.  He then returned to California as Assistant Professor at the Veterans Administration Hospital in Loma Linda, California followed by serving in the US Air Force Medical Corp in Japan and Texas. While in the Air Force he continued clinical research, and then returned to academia by completing a transplant fellowship at the University of Colorado, Denver.  He then served as Assistant Professor and transplant hepatologist at Saint Louis University (SLU), St. Louis, Missouri.  In 2006, he completed a Master of Public Health at SLU.   From 2006, he was Medical Director of Liver Transplantation at the University of North Carolina (UNC), Chapel Hill, and became a Professor of Medicine at UNC before joining the FDA in 2020.  Since 2007, he has been a Co-Principle Investigator in the US Drug-Induced Liver Injury Network (DILIN) and remains Co-Chair of the DILIN’s Causality Committee.  

    Insook Kim

    Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.  She served as a planning committee member for the public workshops on the clinical pharmacology and drug development for liver diseases, and the assessment of PK in hepatic impairment. Dr. Kim is a member of a guidance working group for hepatic impairment study.  Prior to joining FDA, Dr. Kim received a doctoral degree in Pharmaceutics from the University of Michigan and conducted post-doctoral research on nuclear receptors including FXR using transgenic animal models at the National Cancer Institute. She earned a master’s degree in Pharmacy from Seoul National University, and a bachelor’s degree in Pharmacy from Ewha Womens University in Korea.  Her area of interest is translational clinical pharmacology to optimize the drug development and therapeutics. 

    Gerd Kullak-Ublick

    Gerd Kullak-Ublick, MD is a Professor of Clinical Pharmacology and Toxicology at the University of Zurich and Department Head at the University Hospital Zurich, Switzerland. He additionally serves as the Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team at Novartis Pharma, Basel. Dr. Kullak-Ublick went to medical school at the Universities of Bonn, Stanford, London and Munich and received his MD from Munich University in 1990.  Dr. Kullak-Ublick served his residency in Internal Medicine, Gastroenterology and Clinical Pharamacology/Toxicology at the University Hospitals of Munich and Zurich and conducted his postdoctoral research in Zurich, in collaboration with Allan Wolkoff at the Liver Centre, Albert Einstein College of Medicine, Bronx/New York. He obtained Board Certification in Internal Medicine (1998), Gastroenterology (2002) and Clinical Pharmacology and Toxicology (2005). He is coauthor of the 2019 EASL Clinical Practice Guideline on Drug-Induced Liver Injury, as well as on the 2020 CIOMS consensus report on Drug-Induced Liver Injury.

    Mala Maini

    Mala Maini, MD, PhD is a Professor of Viral Immunology in the Division of Infection and Immunity at UCL, London and works as a Consultant Physician in the viral hepatitis clinic. Her lab researches liver immunity and immunopathology, focusing on cellular interactions and metabolic constraints. By dissecting the immune correlates of viral persistence and liver damage, the Maini lab aims to contribute to the development of novel immunotherapeutic strategies for hepatitis B and hepatocellular carcinoma. Mala was awarded the Wellcome Trust Senior Investigator Awards in 2013 and 2019 and elected to the Academy of medical Sciences in 2016. Work in the Maini lab is also funded by the Cancer Research UK, EU Horizon 2020, Medical Research Foundation, NIHR, UKRI, British Infection Association.

    Victor J. Navarro

    Victor J. Navarro, MD, MHCM, FAASLD earned his MD from the Pennsylvania State College of Medicine and completed medical residency followed by chief residency in Internal Medicine at Temple University.  Thereafter, he obtained fellowship training in Gastroenterology, Hepatology, and Hepatobiliary Endoscopy at Yale University.  In 1994, he joined the faculty of the Yale University School of Medicine until he returned to Philadelphia in 2002, as Chief of Hepatology and Medical Director for Liver Transplantation at Thomas Jefferson University.  While at Jefferson, he started a Transplant Hepatology Fellowship program, and rose to the rank of Professor of Medicine, Pharmacology and Experimental Therapeutics.  In 2012, Dr. Navarro joined the Einstein Healthcare Network as Chairman of the Division of Hepatology, and Medical Director for Liver Transplantation. In 2016, he became the founding Medical Chair of the Department of Digestive Disease and Transplantation.  In 2019, Dr. Navarro was awarded his master’s in healthcare management from Harvard University.  He was named the Paul J. Johnson Chair for the Department of Medicine at Einstein in 2020 and is Professor of Medicine at the Sidney Kimmel Medical College, Philadelphia. 

     Dr. Navarro has over 130 publications including peer-reviewed scientific papers, topical reviews, and book chapters.  Dr. Navarro is funded by the National Institutes of Health for his work with the Drug Induced Liver Injury Network where he focuses on liver injury resulting from herbal and dietary supplements.  He is also funded by the Patient Centered Outcomes Research Institute as the Principal Investigator of a multi-site study designed to determine the optimal model for delivery of palliative care to patients with advanced stage liver disease.  

    Lorraine Pelosof

    Lorraine Pelosof, MD grew up in Dallas and graduated from The University of Texas at Austin. She completed her MD and her PhD in Molecular and Cell Biology at Washington University in St. Louis and then completed her Internal Medicine Residency at The University of Texas Southwestern Medical Center. Following residency, she did her fellowship training in Medical Oncology at Johns Hopkins where her research focused on DNA promoter methylation in gastrointestinal tumors.  After serving as an Assistant Professor in the Division of Hematology/Oncology at UT Southwestern, she moved back to Maryland where she is a Medical Officer on the GI oncology team in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration. 

    William Proctor

    Will Proctor, PhD, DABT is a Senior Scientist and Senior Director of Predictive Toxicology in the Department of Safety Assessment at Genentech, Inc. Prior to joining Genentech in 2013, Dr. Proctor earned his BS in Chemistry from Trinity College  and PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in the laboratory of Dr. Dhiren Thakker with a focus on drug transport and pharmacokinetics.  He then performed postdoctoral training at the National Institutes of Health in the laboratory of Dr. Lance Pohl, with research centered on immune mechanisms of drug-induced liver injury (DILI). Will is a board-certified toxicologist and organizational leader with 10 years of experience in investigative and discovery toxicology. At Genentech, Dr. Proctor serves as the Senior Director of Predictive Toxicology, where he oversees the Investigative Toxicology Laboratory, Complex In Vitro Systems Laboratory, and non-clinical safety support for the Small-Molecule Drug Discovery (SMDD) organization. He is also actively involved in several cross-pharma consortia, with leadership roles in the Innovation and Quality (IQ) Microphysiological Systems Affiliate and the Non-clinical Working Group of the IQ DILI Affiliate.  In addition to these activities, Will has continued his research in mechanisms of DILI, including identifying and qualifying preclinical tools to better assess hepatotoxicity risk during drug discovery. 

    K. Rajender Reddy

    K. Rajender Reddy, MD, FAASLD is the Ruimy Family President’s Distinguished Professor of Medicine and Professor of Medicine in Surgery in the Division of Gastroenterology/Hepatology at the University of Pennsylvania. He is the Director of Hepatology, Medical Director of Liver Transplantation, and the Director of the Viral Hepatitis Center. He is a Fellow of the American College of Physicians, American College of Gastroenterology, the Royal College of Physicians, and the American Association for the Study of Liver Diseases. He has held several Visiting Professorships at Medical Schools throughout the World. He has trained and mentored, over the years, several fellows and research assistants, towards a career path in health care and research. He served on several committees for AASLD and was a Councilor-at-Large for 3 years. Dr. Reddy is also a recipient of AASLD’s Distinguished Educator/Mentor Award in 2019.

    Dr. Reddy has authored or co-authored several papers on a spectrum of hepatobiliary topics that include liver transplantation, chronic C viral hepatitis, acute on chronic liver failure, and hepatocellular carcinoma. In addition, he has edited and contributed to several textbooks, and has participated in numerous scientific presentations at National and International meetings. He has been the recipient of both federal and non-federal funding for clinical research.      

    Arie Regev

    Arie Regev, MD, FAASLD is a gastroenterologist and hepatologist working in the Global Patient Safety organization of Eli-Lilly and Company. He heads Lilly’s Safety Advisory Hub and is the chair of Lilly’s Liver Safety Advisory Committee. Dr. Regev is the founding co-chair of the IQ-DILI initiative, and a co-chair of the CIOMS DILI working group. He is a member of the steering committee and a co-chair the immunotherapy working group of the IQ DILI initiative. Dr. Regev is an associate professor of medicine at the division of gastroenterology and hepatology of Indiana University School of Medicine. Prior to joining Eli-Lilly he was an associate professor of medicine and director of the hepatology training program of the University of Miami School of Medicine.

     Dr. Regev received his MD from the Hebrew University in Jerusalem, Israel. He completed residency in medicine and fellowship in gastroenterology at Rabin Medical Center and Tel Aviv University, and completed clinical fellowship in hepatology and transplant hepatology at the division of hepatology of the University of Miami, Florida.

     Dr. Regev has conducted numerous clinical trials in the field of viral hepatitis, liver transplantation, and drug induced liver injury. He was the principal investigator of several NIH funded and industry supported clinical trials in the areas of viral hepatitis, nonalcoholic fatty liver disease, drug induced liver injury, and liver transplantation. He is the author of numerous publications in major medical journals and several chapters in leading medical textbooks. Dr. Regev received teaching and research awards at the University of Miami and Tel Aviv University. He joined Eli-Lilly and the Global Patient Safety organization in 2007.

    Mark W. Russo

    Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. At the American Association for the Study of Liver Diseases, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine.  He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.

    Walter L Straus

    Walter L Straus, MD, MPH, FACP is Associate Vice-President and Therapeutic Area Head for Vaccines and Infectious Disease Therapeutics within Global Clinical Safety and Pharmacovigilance at Merck & Co., Inc. In this capacity his team is responsible for overseeing safety assessment of clinical research as well as post-licensure safety monitoring and assessment for the portfolio of Merck vaccines and infectious disease therapeutics.  

     His training includes Harvard College (A.B.) medicine (SUNY-Buffalo and The Johns Hopkins University), gastroenterology/hepatology (UNC-Chapel Hill), and epidemiology (The Johns Hopkins University). He was formerly on staff at the National Center for Infectious Diseases at the CDC (Atlanta), and is a current member of US HHS Secretary’s Advisory Board on Human Research Protection (SACHRP). At Merck, he oversees the company’s Organ-Specific Safety Boards, which is an internal resource providing sub-specialty expertise to product development teams.  

    Jack Uetrecht

    Jack Uetrecht, PhD is Professor of Pharmacy and Medicine and held the Canada Research Chair in Adverse Drug Reactions from 2001 to 2015.  His research is focused on the mechanisms of idiosyncratic drug reactions with an emphasis on reactive metabolites and immune mechanisms, and he consults for the pharmaceutical industry on problems with idiosyncratic drug reactions. He received his PhD in organic chemistry at Cornell University in 1972, MD at Ohio State University in 1975, and did his internal medical residency at the University of Kansas Medical Center from 1975-1978.  He completed his clinical pharmacology fellowship in 1981 at Vanderbilt University and then joined the faculty as an assistant professor.  He moved to the University of Toronto in 1985 as an associate professor and was the associate dean of pharmacy from 1994 to 1998.  He is a Fellow of the American College of Physicians and Canadian Academy of Health Sciences.  He received the Janssen-Ortho Research award in 2001, the Student’s Administrative Council Undergraduate Teaching Award in 2005, and was voted Teacher of the Year by the 3rd year class in both 2007 and 2008.  He received the Vos Award for Lifetime Career Achievement in Immunotoxicology from the Society of Toxicology in 2018 and the STC Gabriel Plaa Award of Distinction in 2019.  He has over 170 research publications, 35 book chapters, and has published a book with Bill Trager on drug metabolism.  

    Elizabeth C. Verna

    Elizabeth C. Verna, MD, MS is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist. In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.